利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

115 条记录 (耗时 0.062 秒)

    Composition of a n-carboxymethylated tetraazacyclododecane chelating agent, a paramagnetic metal and excess calcium ions for MRI
    2.
    发明授权
    Composition of a n-carboxymethylated tetraazacyclododecane chelating agent, a paramagnetic metal and excess calcium ions for MRI 失效
    N-羧甲基化四氮杂环十二烷螯合剂，顺磁金属和过量钙离子的组成

    公开(公告)号：US5219553A

    公开(公告)日：1993-06-15

    申请号：US743212

    申请日：1991-08-09

    申请人： Karl F. Kraft ,  Steven C. Quay ,  Scott M. Rocklage ,  Dilip Worah

    发明人： Karl F. Kraft ,  Steven C. Quay ,  Scott M. Rocklage ,  Dilip Worah

    IPC分类号： A61K49/06 ,  C07D259/00 ,  C07F5/00 ,  C07F9/38 ,  C07F13/00 ,  G01R33/28

    CPC分类号： G01R33/5601 ,  A61K49/06 ,  C07D259/00 ,  C07F13/005 ,  C07F5/003 ,  C07F9/3817 ,  Y10S424/90 ,  Y10S436/806 ,  Y10S514/836 ,  Y10S514/922 ,  Y10T436/24

    摘要： Magnetic resonance imaging contrast media used to affect the relaxation times of atoms in body tissues undergoing NMR diagnosis are disclosed. Such media comprise (1) a paramagnetic, physiologically compatible complex of (a) a chelant consisting of a N-carboxy methylated tetraazacyclododecane, and (b) a paramagnetic ion of a lanthanide element of atomic numbers 59-70, or of a transition metal of atomic numbers 21-29, 42 or 44, or a physiologically compatible salt of such a complex, and (2) a toxicity-reducing amount of labile calcium ions. The labile calcium ions can be derived from a source other than a salt of said chelant, e.g. an inorganic or organic calcium salt. NMR image-enhancing compositions comprising NMR image-enhancing effective amounts of said contrast media and pharmaceutically acceptable diluents are also disclosed.

    摘要翻译： 公开了用于影响经历NMR诊断的身体组织中的原子的弛豫时间的磁共振成像造影剂。 这种培养基包括（1）由（a）由N-羧基甲基化四氮杂环十二烷组成的螯合剂和（b）原子序数59-70的镧系元素的顺磁离子或过渡金属 的原子序数21-29,42或44，或这种络合物的生理上相容的盐，和（2）不稳定的钙离子的毒性减少量。 不稳定的钙离子可以衍生自除所述螯合剂的盐之外的来源，例如， 无机或有机钙盐。 还公开了包含NMR图像增强有效量的所述造影剂和药学上可接受的稀释剂的NMR图像增强组合物。

    NMR imaging with paramagnetic polyvalent metal salts of poly-(acid-alkylene-amino)-alkanes
    3.
    发明授权
    NMR imaging with paramagnetic polyvalent metal salts of poly-(acid-alkylene-amino)-alkanes 失效
    聚（亚烷基 - 氨基） - 烷烃的顺磁多价金属盐的NMR成像

    公开(公告)号：US5039512A

    公开(公告)日：1991-08-13

    申请号：US057709

    申请日：1987-06-15

    申请人： Karl F. Kraft ,  Steven C. Quay ,  Scott M. Rocklage ,  Dilip Worah

    发明人： Karl F. Kraft ,  Steven C. Quay ,  Scott M. Rocklage ,  Dilip Worah

    IPC分类号： A61K49/06 ,  C07D259/00 ,  C07F5/00 ,  C07F9/38 ,  C07F13/00 ,  G01R33/28

    CPC分类号： G01R33/5601 ,  A61K49/06 ,  C07D259/00 ,  C07F13/005 ,  C07F5/003 ,  C07F9/3817 ,  Y10S424/90 ,  Y10T436/24

    摘要： In a method of imaging body tissue in a patient, comprising administering to the patient an effective amount of a pharmaceutical agent for effecting the relaxation times of atoms in body tissues undergoing NMR diagnosis, whereby image contrast is enhanced, said agent comprising an amount, effective to effect such relaxation times, of a paramagnetic, physiologically compatible salt of a physiologically compatible chelate complex of an ion of a lanthanide element of atomic numbers 57-70, or of a transition metal of atomic numbers 21-29, 42, or 44; and a pharmaceutically acceptable carrier, and subjecting the patient to NMR tomography, the improvement wherein said salt of said chelate complex is the calcium or magnesium salt. Such salts are new as are some of the complexing chelates.

    摘要翻译： 在患者体内成像身体组织的方法中，包括向患者施用有效量的用于进行经历核磁共振诊断的身体组织中的原子的松弛时间的药剂，由此增强图像对比度，所述药剂包含有效量 实现这样的松弛时间，原子序数为57-70的镧系元素离子的生理上相容的螯合络合物的顺磁性生理上相容的盐或原子序数21-29,42或44的过渡金属; 和药学上可接受的载体，并对患者进行NMR层析成像，其中所述螯合络合物的所述盐是钙盐或镁盐。 这些盐是一些新的络合螯合物。

    NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
    7.
    发明申请
    NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF 审中-公开
    用于抑制PLK1基因表达的核酸化合物及其用途

    公开(公告)号：US20110136233A1

    公开(公告)日：2011-06-09

    申请号：US13057743

    申请日：2009-08-05

    申请人： Steven C. Quay ,  Narendra K. Vaish ,  Kathy L. Fosnaugh ,  Shaguna Seth

    发明人： Steven C. Quay ,  Narendra K. Vaish ,  Kathy L. Fosnaugh ,  Shaguna Seth

    IPC分类号： C12N5/00 ,  C07H21/02

    CPC分类号： C12N15/1137 ,  C12N2310/14 ,  C12N2310/32 ,  C12N2310/533

    摘要： The present disclosure provides RNA molecules, for example, meroduplex ribonucleic acid molecules (mdRNA), capable of decreasing or silencing gene expression of PLK1 gene. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a PLK1 mRNA. Also provided are methods of decreasing expression of a PLK1 gene in a cell or in a subject to treat a PLK family member-related disease.

    摘要翻译： 本公开提供了能够降低或沉默PLK1基因的基因表达的RNA分子，例如meroduplex核糖核酸分子（mdRNA）。 本公开的mdRNA包含至少三条链，其组合形成由切口或间隙分开的至少两个不重叠的双链区域，其中一条链与PLK1mRNA互补。 还提供减少细胞或受试者中PLK1基因表达以治疗PLK家族成员相关疾病的方法。

    Compositions for enhanced epithelial permeation of neuropeptide Y for treating obesity
    8.
    发明授权
    Compositions for enhanced epithelial permeation of neuropeptide Y for treating obesity 失效
    用于增强神经肽Y上皮渗透以治疗肥胖症的组合物

    公开(公告)号：US07863245B2

    公开(公告)日：2011-01-04

    申请号：US12234547

    申请日：2008-09-19

    申请人： Steven C. Quay

    发明人： Steven C. Quay

    IPC分类号： A61K38/22 ,  A61K38/17 ,  C07K14/435 ,  C07C217/28

    CPC分类号： A61K9/0043 ,  A61K38/1709

    摘要： Pharmaceutical compositions comprising PYY(3-36) or Neuropeptide Y (NPY), a cyclodextrin, and a compound selected from phosphatidylcholine or diglyceride, wherein the PYY(3-36) or Neuropeptide Y (NPY) is present in an amount effective to alleviate one or more symptom(s) of obesity in a subject, and the cyclodextrin and the compound selected from phosphatidylcholine or diglyceride are present in an amount sufficient to enhance epithelial permeation.

    摘要翻译： 包含PYY（3-36）或神经肽Y（NPY），环糊精和选自磷脂酰胆碱或甘油二酯的化合物的药物组合物，其中PYY（3-36）或神经肽Y（NPY）以有效缓解的量存在 受试者中一种或多种肥胖症状，以及环糊精和选自磷脂酰胆碱或甘油二酯的化合物以足以增加上皮渗透的量存在。

    NUCLEIC ACID COMPOUNDS FOR INHIBITING MYC GENE EXPRESSION AND USES THEREOF
    9.
    发明申请
    NUCLEIC ACID COMPOUNDS FOR INHIBITING MYC GENE EXPRESSION AND USES THEREOF 审中-公开
    用于抑制MYC基因表达的核酸化合物及其用途

    公开(公告)号：US20100055782A1

    公开(公告)日：2010-03-04

    申请号：US12529138

    申请日：2008-03-03

    申请人： Steven C. Quay ,  James McSwiggen ,  Narendra K. Vaish ,  Mohammad Ahmadian

    发明人： Steven C. Quay ,  James McSwiggen ,  Narendra K. Vaish ,  Mohammad Ahmadian

    IPC分类号： C12N5/071 ,  C07H21/02 ,  C12N5/02

    CPC分类号： C12N15/1135 ,  C12N2310/14

    摘要： The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing MYC gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-over-lapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a MYC mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a MYC gene in a cell or in a subject to treat a MYC-related disease.

    摘要翻译： 本公开提供能够降低或沉默MYC基因表达的meroduplex核糖核酸分子（mdRNA）。 本公开的mdRNA包含至少三条链，其组合形成由切口或间隙分开的至少两个非重叠双链区域，其中一条链与MYC mRNA互补。 此外，meroduplex可以具有至少一个用5-甲基尿苷取代的尿苷，被锁定的核酸替代的核苷，或任选的其它修饰，以及它们的任何组合。 还提供减少细胞或受试者中MYC基因表达以治疗MYC相关疾病的方法。

    NUCLEIC ACID COMPOUNDS FOR INHIBITING BCL2 GENE EXPRESSION AND USES THEREOF
    10.
    发明申请
    NUCLEIC ACID COMPOUNDS FOR INHIBITING BCL2 GENE EXPRESSION AND USES THEREOF 审中-公开
    用于抑制BCL2基因表达的核酸化合物及其用途

    公开(公告)号：US20100041140A1

    公开(公告)日：2010-02-18

    申请号：US12529011

    申请日：2008-02-29

    申请人： Steven C. Quay ,  James McSwiggen ,  Narendra K. Vaish ,  Mohammad Ahmadian

    发明人： Steven C. Quay ,  James McSwiggen ,  Narendra K. Vaish ,  Mohammad Ahmadian

    IPC分类号： C12N5/07 ,  C07H21/02

    CPC分类号： C12N15/1135 ,  C12N2310/14 ,  C12N2310/53

    摘要： The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing BCL2 gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-over-lapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a BCL2 mRNA. In addition, the meroduplex may have at least one uridine is a 5-methyluridine, a nucleoside is a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a BCL2 gene in a cell or in a subject to treat a BCL2-related disease.

    摘要翻译： 本公开提供能够降低或沉默BCL2基因表达的meroduplex核糖核酸分子（mdRNA）。 本公开的mdRNA包含至少三条链，其组合形成由切口或间隙分开的至少两个非重叠双链区域，其中一条链与BCL2 mRNA互补。 此外，meroduplex可以具有至少一个尿苷是5-甲基尿苷，核苷是锁定的核酸或任选的其它修饰，以及它们的任何组合。 还提供减少细胞或受试者中BCL2基因表达以治疗BCL2相关疾病的方法。